X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (365) 365
humans (359) 359
female (355) 355
ovarian cancer (324) 324
ovarian neoplasms - drug therapy (298) 298
platinum-resistant (283) 283
index medicus (244) 244
chemotherapy (235) 235
middle aged (175) 175
aged (164) 164
obstetrics & gynecology (150) 150
cancer (148) 148
adult (145) 145
paclitaxel (144) 144
carcinoma (141) 141
antineoplastic combined chemotherapy protocols - therapeutic use (118) 118
gynecologic-oncology-group (117) 117
pegylated liposomal doxorubicin (115) 115
ovarian neoplasms - pathology (113) 113
phase-ii trial (112) 112
neoplasm recurrence, local - drug therapy (110) 110
cisplatin (108) 108
drug resistance, neoplasm (101) 101
platinum-resistant ovarian (99) 99
antineoplastic agents - therapeutic use (91) 91
phase-ii (79) 79
topotecan (79) 79
care and treatment (75) 75
treatment outcome (75) 75
carboplatin (72) 72
aged, 80 and over (71) 71
disease-free survival (70) 70
gemcitabine (66) 66
hematology, oncology and palliative medicine (63) 63
antineoplastic combined chemotherapy protocols - adverse effects (61) 61
bevacizumab (61) 61
neoplasms, glandular and epithelial - drug therapy (60) 60
epithelial ovarian (58) 58
research (56) 56
carcinoma, ovarian epithelial (55) 55
therapy (55) 55
pharmacology & pharmacy (54) 54
peritoneal neoplasms - drug therapy (53) 53
trial (53) 53
deoxycytidine - analogs & derivatives (52) 52
platinum resistant (52) 52
obstetrics and gynecology (50) 50
recurrent epithelial ovarian (50) 50
drug administration schedule (49) 49
open-label (48) 48
paclitaxel - administration & dosage (46) 46
ovarian neoplasms - mortality (45) 45
prognosis (45) 45
recurrent ovarian cancer (44) 44
health aspects (41) 41
clinical trials (40) 40
double-blind (40) 40
primary peritoneal carcinoma (40) 40
relapse (40) 40
deoxycytidine - administration & dosage (39) 39
liposomal doxorubicin (38) 38
neoplasm staging (38) 38
stage-iii (38) 38
epithelial ovarian cancer (37) 37
analysis (36) 36
antineoplastic agents - adverse effects (36) 36
drug therapy (36) 36
fallopian-tube (36) 36
topotecan - administration & dosage (36) 36
antineoplastic agents (35) 35
doxorubicin - administration & dosage (35) 35
recurrent (35) 35
retrospective studies (35) 35
survival (35) 35
antineoplastic combined chemotherapy protocols - administration & dosage (34) 34
cell lung-cancer (34) 34
cyclophosphamide (34) 34
medicine & public health (34) 34
ovarian neoplasms - therapy (33) 33
salvage therapy (33) 33
survival rate (33) 33
antimitotic agents (32) 32
antitumor-activity (32) 32
fallopian tube neoplasms - drug therapy (32) 32
ovarian neoplasms - metabolism (32) 32
phase-iii trial (32) 32
antineoplastic agents - pharmacology (31) 31
clinical trials as topic (31) 31
dose-response relationship, drug (31) 31
solid tumors (31) 31
survival analysis (31) 31
targeted therapy (31) 31
angiogenesis (30) 30
cisplatin - administration & dosage (30) 30
combination (30) 30
platinum (30) 30
animals (29) 29
platinum-resistant ovarian cancer (29) 29
antineoplastic agents - administration & dosage (28) 28
cancer therapies (28) 28
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (500) 500
German (10) 10
Spanish (4) 4
French (3) 3
Korean (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 2010, Volume 46, Issue 9, pp. 1573 - 1579
Journal Article
Seminars in Cancer Biology, ISSN 1044-579X, 08/2018, Volume 51, pp. 160 - 169
Journal Article
Oncogene, ISSN 0950-9232, 05/2013, Volume 32, Issue 22, pp. 2767 - 2781
Cisplatin and paclitaxel are standard chemotherapy for metastatic ovarian cancer, but with limited efficacy. Cancer stem/progenitor cells (or tumor-initiating... 
b-catenin | chemoresistance | c-Kit | ovarian cancer | ABCG2 | beta-catenin | SURFACE EPITHELIUM | ONCOLOGY-GROUP | BIOCHEMISTRY & MOLECULAR BIOLOGY | PLATINUM-RESISTANT | CHRONIC MYELOID-LEUKEMIA | CELL BIOLOGY | PHASE-II TRIAL | ONCOLOGY | SEROUS CARCINOMA | GENETICS & HEREDITY | IMATINIB MESYLATE | EPITHELIAL OVARIAN | CLINICOPATHOLOGICAL FEATURES | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Paclitaxel - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Tumor Microenvironment | Neoplasm Proteins - metabolism | Proto-Oncogene Proteins c-kit - metabolism | Wnt Proteins - metabolism | Cell Hypoxia | Neoplastic Stem Cells - metabolism | RNA Interference | Cell Transformation, Neoplastic - genetics | ATP-Binding Cassette Transporters - metabolism | Female | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Cell Survival - drug effects | Cisplatin - pharmacology | Pyrimidines - pharmacology | Cell Transformation, Neoplastic - metabolism | Imatinib Mesylate | Piperazines - pharmacology | beta Catenin - metabolism | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Wnt Signaling Pathway - drug effects | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2018, Volume 81, Issue 1, pp. 17 - 38
Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of... 
Medicine & Public Health | Biological drugs | Targeted therapy | Clinical trials | Oncology | Cancer Research | Pharmacology/Toxicology | Ovarian cancer | ADVANCED EPITHELIAL OVARIAN | TRIFUNCTIONAL ANTIBODY CATUMAXOMAB | MALIGNANT ASCITES | PHASE-II | OPEN-LABEL | MAINTENANCE THERAPY | PLATINUM-RESISTANT | ONCOLOGY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | PARP INHIBITORS | FOLATE RECEPTOR-ALPHA | ErbB Receptors - antagonists & inhibitors | Humans | Neoplasm Recurrence, Local - therapy | Precision Medicine - economics | Infusions, Parenteral | Neoplasm Recurrence, Local - drug therapy | Palliative Care | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Antineoplastic Agents - administration & dosage | Cytoreduction Surgical Procedures | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Folic Acid Antagonists - therapeutic use | Cost-Benefit Analysis | Immunotherapy | Hyperthermia, Induced | Angiogenesis Inhibitors - therapeutic use | Ovarian Neoplasms - therapy | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Antimitotic agents | Chemotherapy | Chronic diseases | Antineoplastic agents | Health aspects | Sugars | Folic acid | Monosaccharides | Cancer | Drugs | Medical research | Ovarian carcinoma | Medical services | Poly(ADP-ribose) polymerase | Drug development | Cancer therapies | Disease control | Patients | Polymerase | Angiogenesis | Signaling | Inhibitors | Ribose | Surgery | Review
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 01/2011, Volume 9, Issue 1, pp. 82 - 113
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2017, Volume 28, Issue suppl_8, pp. viii57 - viii60
Journal Article
Journal Article